Business Standard

Monday, December 23, 2024 | 10:38 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

USFDA grants Orphan Drug Designation to Lupin's mexiletine hydrochloride

Image

Capital Market
Lupin announced that the US Food and Drug Administration (U.S. FDA) has granted Orphan Drug Designation (ODD) to mexiletine hydrochloride for the treatment of myotonic disorders.

The FDA grants ODD status to medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jun 08 2020 | 1:35 PM IST

Explore News